Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

计划入组 51 人 · 首次发布于 2019 年 12 月 13 日

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

计划入组 50 人 · 首次发布于 2025 年 6 月 10 日

Experience of Having Chronic Graft-Versus-Host Disease

计划入组 187 人 · 首次发布于 2006 年 7 月 17 日

Graft-versus-host disease therapeutics (Mallinckrodt)

Belumosudil(Rezurock)

C₂₆H₂₄N₆O₂ · Rx

Graft-versus-host disease therapy(Applied StemCell, Inc.)

Kineta Chronic Pain LLC

United States

Vascular Graft Solutions Ltd.

Israel

Theriva Biologics

United States

Belumosudil Shows Promise in Treating Heavily Pretreated Chronic Graft-versus-Host Disease

Ibrutinib Shows Promise in Treating Chronic Graft-Versus-Host Disease

FDA Approves Belumosudil for Chronic Graft-Versus-Host Disease Treatment